Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Mild intellectual disability, Global developmental delay, and Compulsive behaviors; and common findings: Brain shrinkage (cerebral atrophy), Dysmetria, Shrinkage of the cerebellum (cerebellar atrophy), and Ataxia and others. 17 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Brain shrinkage (cerebral atrophy), Mild intellectual disability, Global developmental delay |
PITRM1 function has not been fully characterized.
Spinocerebellar ataxia, autosomal recessive 30 is associated with mutations in the PITRM1 gene on chromosome 10.
Genetic testing for PITRM1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for spinocerebellar ataxia, autosomal recessive 30 has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 6 common features.
No clinical trials have been registered for spinocerebellar ataxia, autosomal recessive 30.
11 publications have been identified in PubMed for spinocerebellar ataxia, autosomal recessive 30. Research spans Clinical Trial Publication (27%), Diagnostic / Biomarker (18%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 3 | 27% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 6:10 PM UTC
Online Mendelian Inheritance in Man
Lab test results | 4 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Increased circulating pyruvate concentration, Increased circulating lactate concentration |
Muscles | 2 | Brain shrinkage (cerebral atrophy), Shrinkage of the cerebellum (cerebellar atrophy) |
Testing and diagnosis research
2 |
18% |
Research summaries | 2 | 18% |
Patient case studies | 2 | 18% |
Disease patterns and progression | 1 | 9% |
New treatment approaches | 1 | 9% |
Aloisio S (2025). [PMID: 40824590](https://pubmed.ncbi.nlm.nih.gov/40824590/). *Neurol Sci*. [Case Report / Case Series]
Jayanth N (2025). [PMID: 39638147](https://pubmed.ncbi.nlm.nih.gov/39638147/). *SLAS Discov*. [Gene Therapy / Novel Therapeutics]
Lessard I (2025). [PMID: 40332679](https://pubmed.ncbi.nlm.nih.gov/40332679/). *Cerebellum*. [Clinical Trial Publication]
Di Folco C (2025). [PMID: 40832806](https://pubmed.ncbi.nlm.nih.gov/40832806/). *Mov Disord*. [Diagnostic / Biomarker]
Novis LE (2025). [PMID: 39920364](https://pubmed.ncbi.nlm.nih.gov/39920364/). *Cerebellum*. [Review / Meta-Analysis]
Lessard I (2025). [PMID: 40095137](https://pubmed.ncbi.nlm.nih.gov/40095137/). *Cerebellum*. [Clinical Trial Publication]
Milne SC (2025). [PMID: 39520242](https://pubmed.ncbi.nlm.nih.gov/39520242/). *Ann Neurol*. [Clinical Trial Publication]
Beichert L (2024). [PMID: 38847438](https://pubmed.ncbi.nlm.nih.gov/38847438/). *Mov Disord*. [Epidemiology / Natural History]
Scaravilli A (2024). [PMID: 38847051](https://pubmed.ncbi.nlm.nih.gov/38847051/). *Mov Disord*. [Diagnostic / Biomarker]
Ormond C (2024). [PMID: 39080331](https://pubmed.ncbi.nlm.nih.gov/39080331/). *Sci Rep*. [Review / Meta-Analysis]